ft 23 mar 94 survey pharmaceut 12 demand econom specialist new drug must safe use produc must prove buyer product clearli cost effect drug develop cost want health econom specialist excel pay prospect world biggest corpor perk includ travel rub shoulder top manag key role success launch product potenti sale pound 1bn year messag world big pharmaceut compani put one europ top compani recent approach professor alan maynard centr health econom york univers uk ask name five phd could recruit receiv answer want say professor maynard demand arisen structur drug industri chang compani sold doctor hospit sell govern insur us corpor rang industri sector organis actual pay medicin begin flex buy power muscl drug compani mean longer enough show drug safe work although still requir regulatori bodi washington base food drug administr task includ demonstr payer drug cost effect disciplin even name pharmacoeconom nowher import new area clearer australia sinc januari 1993 drug submit approv must accompani result clinic trial econom impact analysi analysi must base comparison exist treatment must cover price drug impact spend medic servic time patient spend occupi hospit bed sometim case exampl elderli patient social servic cost includ australian scheme still earli day much yet finalis especi question object measur patient qualiti life effect drug compani alreadi far reach econom simpl new product margin improv exist one comparison made cost drug differ long averag patient spend hospit howev breakthrough treatment submit approv often high price drug compani work hard demonstr conclus make econom sens therefor bulk econom workload fall compani invent breakthrough drug biggest research base compani mostli us uk swiss glaxo uk exampl alreadi 50 employe area anglo us compani smithklin beecham less 10 recruit rapidli surprisingli compani sought make best use invest outsid australia well insid economist work use market effort may help persuad govern regulatori bodi allow high price charg provid econom benefit felt elsewher swiss compani sandoz exampl health econom part market oper began studi show transplant kidney cheaper long term dialysi sandoz make sandimmun immunosuppress use transplant oper cut chanc new kidney reject sale grow rapidli drug alreadi world top 20 seller compani regard pharmacoeconom programm success sandoz extend pharmacoeconom programm studi skin diseas could help sale fungal treatment lamisil sale sfr50m 1992 stockbrok jame capel forecast 1996 compani second biggest product sale sfr600m year economist also becom involv much earlier stage drug industri develop chain glaxo exampl advis research develop depart like econom effect propos new product decis made earlier whether worthwhil continu research product may find favour increasingli cost consciou healthcar environ research come favour drug industri uk govern fund research independ academ cost treat depress blood cholesterol uncondit pleas smithklin beecham whose new anti depress seroxat promis one biggest success 1990 merck whose mevacor zocor cholesterol lower drug combin sale dollar 2bn year role pharmacoeconom drug industri seem set increas kind work australian experi attract attent govern healthcar buyer around world canada alreadi issu draft guidelin pharmacoeconom studi treatment regim us healthcar organis demand know compar cost compet treatment budget consciou politician privat sector healthcar buyer find hard resist use analys negoti drug sell price pharmaceut industri